

Novacyt S.A.
("Novacyt", the "Company" or the "Group")

Launch of LightBench® Discover

Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the launch of LightBench® Discover, a high-precision 3-in-1 instrument for genomic research labs conducting long-read sequencing.

The concept for the LightBench® Discover was developed following a close collaboration with PacBio®, where Yourgene Health became a PacBio® Compatible Partner for the original LightBench® in November 2023. As part of product development for LightBench® Discover, Novacyt deployed prototype instruments into the field to gather customer feedback on user experience, develop protocols and run real world samples to assess the instruments' performance.

LightBench® Discover is an integrated single benchtop solution that replaces the need for multiple instruments in labs conducting long-read HiFi sequencing, who need both large fragment analytics (larger than 20 kilobases) and DNA size selection. In addition, LightBench® Discover also delivers fluorometric quantification. Researchers benefit from a cost-effective, high-performance system that enhances efficiency, whilst eliminating the need to invest in multiple instruments with separate service contracts and software platforms. The product has extended capabilities (compared to the original LightBench®) for large fragment analytics up to 150 kilobases, along with size selection and quantification functions, making it ideal for research applications utilising long read sequencing on the PacBio Revio® or Vega™ systems.

Today, the Company has released the Technical Note showcasing data from its collaborator The CoLab at the HudsonAlpha Institute for Biotechnology in Alabama, US. The Technical Note will be hosted on the Company's website <https://yourgenehealth.com/our-products/instruments/lightbench-discover/> and on the PacBio® Compatible Partners webpage <https://www.pacb.com/3rd-party-compatible-products/>.

Lyn Rees, CEO of Novacyt, commented "The product development and launch of LightBench® Discover is a significant achievement for the Novacyt team, and I would like to congratulate everyone for their efforts. LightBench® Discover's 3-in-1 technology provides cost efficiencies, enhances quality control, simplifies workflows and delivers high-accuracy analytics which have all been designed around our customer needs. This new offering from Novacyt will only further strengthen our existing partnerships and keep us at the forefront of genomic research."

Contacts

Novacyt SA

Lyn Rees, Chief Executive Officer
Steve Gibson, Chief Financial Officer

<https://novacyt.com/investors>

Via Walbrook PR

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

Deutsche Numis (Joint Broker)

Freddie Barnfield / Duncan Monteith / Michael Palser

+44 (0)20 7260 1000

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com / y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR)

Paul McManus / Lianne Applegarth
Alice Woodings

+44 (0)20 7933 8780 or novacyt@walbrookpr.com

+44 (0)7980 541 893 / +44 (0)7584 391 303

+44 (0)7407 804 654

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical

Broad portfolio of human clinical *in vitro* diagnostic products, workflows and services focused on three therapeutic areas:

- Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
- Precision Medicine: DPYD genotyping assay
- Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation

Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:

- Ranger® Technology: automated DNA sample preparation and target enrichment technology

- genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

Research Use Only Range of services for the life sciences industry:

- Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
- Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCPKQBPCBKDAOD